Compare DUO & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DUO | TOVX |
|---|---|---|
| Founded | 2011 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 7.3M |
| IPO Year | 2019 | 2006 |
| Metric | DUO | TOVX |
|---|---|---|
| Price | $1.95 | $0.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 109.7K | ★ 2.5M |
| Earning Date | 11-19-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $56,189,313.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 48.30 | N/A |
| 52 Week Low | $1.24 | $0.20 |
| 52 Week High | $14.40 | $2.08 |
| Indicator | DUO | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 48.14 | 41.78 |
| Support Level | $1.86 | $0.21 |
| Resistance Level | $2.44 | $0.24 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 37.18 | 23.83 |
Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.